Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 2 Safety and Efficacy Trial of Irinotecan-ChemoSeed Administered Directly Into the Resection Margin in Patients With Surgically Resectable Glioblastoma

NCT07356973 is registered in ClinicalTrials.gov with CRISM Therapeutics LTD as lead sponsor.

NCT NCT07356973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07356973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 2 Safety and Efficacy Trial of Irinotecan-ChemoSeed Administered Directly Into the Resection Margin in Patients With Surgically Resectable Glioblastoma
Lead sponsor
CRISM Therapeutics LTD
Phase
Phase 2
Overall status
Recruiting
Start date
August 20, 2026
Completion date
December 31, 2029
Enrollment
147 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma